Board of Directors of Genetico appointed Igor Zharkikh as the new CEO of the company. He has extensive management experience in both international and Russian companies. Igor Zharkikh at various times held the position of CEO of the pharmaceutical company Sagmel, the network of orthopedic salons Ortek, as well as the network of medical centers Lechu.ru.

Genetico's RAS loss for 6 months of 2025 amounted to 9.2 million rubles, an increase of 5.7% compared to 8.7 million rubles in the previous year. Revenue increased by 56.3% to ₽282.9 million from ₽181 million a year earlier.

Genetico has completed the placement of 7 million additional shares at a price of ₽34 per share. Additional issue was purchased by Artgen Biotech. Company will use the funds raised to repay its debt and develop a portfolio of gene therapy drugs for the treatment of orphan diseases.

Genetico's RAS loss for 3 months of 2025 amounted to ₽20.9 million against a profit of ₽5 million in the previous year. Revenue increased 71.2% to ₽134.2 million vs. ₽78.4 million a year earlier.